UroGen Pharma Hits New 52-Week High of $36.64, Up 182%

UroGen Pharma has reached a significant milestone by hitting a new 52-week high of USD 36.64 on June 29, 2026. This achievement marks a remarkable increase from its 52-week low of USD 12.73, showcasing a substantial growth trajectory over the past year. The company, operating within the Pharmaceuticals & Biotechnology sector, has demonstrated an impressive one-year performance of 182.46%, significantly outpacing the S&P 500's performance of 20.53%. UroGen Pharma's market capitalization stands at USD 836 million, categorizing it as a small-cap company. Despite being in a loss-making position, the company exhibits a strong return on equity of 145.53%, indicating effective management of its equity base. However, it is noteworthy that UroGen Pharma does not offer a dividend yield, and its price-to-book ratio is reported at -7.92. The company's debt-to-equity ratio is slightly negative at -0.02, reflecting a unique financial structure. Overall, UroGen Pharma's recent performance highlights its notable position within the biotechnology landscape.